A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

Maria Grazia Fabrini, Giovanni Silvano, Ivan Lolli, Franco Perrone, Annarita Marsella, Valerio Scotti, Luca Cionini

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalJournal of Neuro-Oncology
Volume92
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

fotemustine
Glioblastoma
Drug Therapy
temozolomide
Survival
Glioma
Disease-Free Survival
Radiotherapy

Keywords

  • Fotemustine
  • Glioblastoma
  • Recurrence
  • Second-line chemotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. / Fabrini, Maria Grazia; Silvano, Giovanni; Lolli, Ivan; Perrone, Franco; Marsella, Annarita; Scotti, Valerio; Cionini, Luca.

In: Journal of Neuro-Oncology, Vol. 92, No. 1, 2009, p. 79-86.

Research output: Contribution to journalArticle

Fabrini, Maria Grazia ; Silvano, Giovanni ; Lolli, Ivan ; Perrone, Franco ; Marsella, Annarita ; Scotti, Valerio ; Cionini, Luca. / A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. In: Journal of Neuro-Oncology. 2009 ; Vol. 92, No. 1. pp. 79-86.
@article{530b32d1967e4146a59bc5399344ae32,
title = "A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma",
abstract = "The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62{\%}. PFS was 6.1 months; PFS-6 was 52{\%} and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.",
keywords = "Fotemustine, Glioblastoma, Recurrence, Second-line chemotherapy, Temozolomide",
author = "Fabrini, {Maria Grazia} and Giovanni Silvano and Ivan Lolli and Franco Perrone and Annarita Marsella and Valerio Scotti and Luca Cionini",
year = "2009",
doi = "10.1007/s11060-008-9739-6",
language = "English",
volume = "92",
pages = "79--86",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

AU - Fabrini, Maria Grazia

AU - Silvano, Giovanni

AU - Lolli, Ivan

AU - Perrone, Franco

AU - Marsella, Annarita

AU - Scotti, Valerio

AU - Cionini, Luca

PY - 2009

Y1 - 2009

N2 - The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.

AB - The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.

KW - Fotemustine

KW - Glioblastoma

KW - Recurrence

KW - Second-line chemotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=59349113568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59349113568&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9739-6

DO - 10.1007/s11060-008-9739-6

M3 - Article

VL - 92

SP - 79

EP - 86

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -